NCT02532257
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
CD20 Positive
Explore clinical trials studying CD20 Positive. Study availability and eligibility vary by location and protocol.
10 public trials
0 recruiting studies
CD20 Positive trial results
NCT01363128
- Conditions
- Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, +24 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT00439556
- Conditions
- CD20 Positive, Hematologic Diseases, Hematologic Neoplasms, +11 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT00880815
- Conditions
- CD20 Positive, Chronic Disease, Chronic Lymphocytic Leukemia, +28 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01729806
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- City of Hope South Pasadena South Pasadena, California, United States
NCT02219737
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States
Active, Not Recruiting
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567
- Conditions
- CCND1 Positive, CCND2 Positive, CCND3 Positive, +14 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT03946878
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, +16 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
NCT01959698
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT04007029
- Conditions
- CD19 Positive, CD20 Positive, Chronic Disease, +33 more
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States